A compound of structural formula I, Wherein R 1 is selected from a hydrogen atom, unsubstituted linear or branched C 1 -C 4 alkyl; wherein R 2 and R 3 are each independently selected from unsubstituted linear or branched C 1 -C 4 alkyl, or R 2 and R 3 , together with the C atoms to which they are attached respectively, form a saturated or unsaturated 3 to 7 membered ring; R 4 and R 5 are each independently selected from the group consisting of hydrogen and halogen, and at least one of R 4 and R 5 is halogen; R 6 is selected from a hydrogen atom, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, hydroxyl or halogen; R 7 is wherein Z is carbonyl, O, S, imino, sulfonyl or , and n is an integer from 0 to 4; W and Y are each independently C, N, O or S, but W and Y cannot both be C at the same time, and when Z is O or S, W is C; R 10 , R 11 , R 12 and R 13 are each independently selected from a hydrogen atom, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 1 -C 6 hydroxyalkyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, hydroxyl, halogen; or R 6 and R 7 together with the C atoms to which they are attached form a 5 to 7 membered heterocycle containing one or more atoms selected from N, O or S, and the 5 to 7 membered heterocycle is substituted by one or more substituents selected from C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 hydroxyalkyl, hydroxyl, halogen, cyano, - NH 2 , -NHR 8 , -NR 8 R 9 , wherein R 8 and R 9 are each independently selected from the group consisting of a hydrogen atom, C 1 -C 6 alkyl and C 1 -C 6 hydroxyalkyl; or a tautomer, a mesomer, a racemate, an enantiomer, a diastereomer, an isotopically-labeled compound, or a mixture thereof; or pharmaceutically acceptable salts or solvates of the compound of structural formula I or its tautomer, mesomer, racemate, enantiomer, diastereomer, isotopically-labeled compound, or a mixture thereof. Wherein R 1 is selected from a hydrogen atom, unsubstituted linear or branched C 1 -C 4 alkyl; wherein R 2 and R 3 are each independently selected from unsubstituted linear or branched C 1 -C 4 alkyl, or R 2 and R 3 , together with the C atoms to which they are attached respectively, form a saturated or unsaturated 3 to 7 membered ring; R 4 and R 5 are each independently selected from the group consisting of hydrogen and halogen, and at least one of R 4 and R 5 is halogen; R 6 is selected from a hydrogen atom, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, hydroxyl or halogen; R 7 is wherein Z is carbonyl, O, S, imino, sulfonyl or , and n is an integer from 0 to 4; W and Y are each independently C, N, O or S, but W and Y cannot both be C at the same time, and when Z is O or S, W is C; R 10 , R 11 , R 12 and R 13 are each independently selected from a hydrogen atom, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 1 -C 6 hydroxyalkyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, hydroxyl, halogen; or R 6 and R 7 together with the C atoms to which they are attached form a 5 to 7 membered heterocycle containing one or more atoms selected from N, O or S, and the 5 to 7 membered heterocycle is substituted by one or more substituents selected from C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 hydroxyalkyl, hydroxyl, halogen, cyano, - NH 2 , -NHR 8 , -NR 8 R 9 , wherein R 8 and R 9 are each independently selected from the group consisting of a hydrogen atom, C 1 -C 6 alkyl and C 1 -C 6 hydroxyalkyl; or a tautomer, a mesomer, a racemate, an enantiomer, a diastereomer, an isotopically-labeled compound, or a mixture thereof; or pharmaceutically acceptable salts or solvates of the compound of structural formula I or its tautomer, mesomer, racemate, enantiomer, diastereomer, isotopically-labeled compound, or a mixture thereof. <EOS>